DORCHESTER WEALTH MANAGEMENT Co Has $7.35 Million Stake in Kenvue Inc. (NYSE:KVUE)

DORCHESTER WEALTH MANAGEMENT Co lowered its stake in shares of Kenvue Inc. (NYSE:KVUE) by 0.9% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 344,070 shares of the company’s stock after selling 3,200 shares during the period. Kenvue makes up approximately 1.5% of DORCHESTER WEALTH MANAGEMENT Co’s portfolio, making the stock its 26th biggest holding. DORCHESTER WEALTH MANAGEMENT Co’s holdings in Kenvue were worth $7,346,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Alerus Financial NA boosted its stake in shares of Kenvue by 0.3% in the 3rd quarter. Alerus Financial NA now owns 191,345 shares of the company’s stock worth $4,426,000 after buying an additional 491 shares during the last quarter. Kiley Juergens Wealth Management LLC boosted its stake in shares of Kenvue by 1.9% in the 4th quarter. Kiley Juergens Wealth Management LLC now owns 27,110 shares of the company’s stock worth $579,000 after buying an additional 500 shares during the last quarter. Principle Wealth Partners LLC boosted its stake in shares of Kenvue by 3.7% in the 4th quarter. Principle Wealth Partners LLC now owns 14,194 shares of the company’s stock worth $303,000 after buying an additional 500 shares during the last quarter. White Pine Capital LLC boosted its stake in shares of Kenvue by 1.0% in the 4th quarter. White Pine Capital LLC now owns 54,572 shares of the company’s stock worth $1,165,000 after buying an additional 542 shares during the last quarter. Finally, Deseret Mutual Benefit Administrators raised its holdings in shares of Kenvue by 29.0% in the 4th quarter. Deseret Mutual Benefit Administrators now owns 2,528 shares of the company’s stock worth $54,000 after purchasing an additional 568 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Trading Up 4.1 %

Shares of KVUE stock opened at $23.31 on Friday. The company’s fifty day simple moving average is $21.31 and its two-hundred day simple moving average is $22.18. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. Kenvue Inc. has a 1 year low of $17.67 and a 1 year high of $24.46. The stock has a market capitalization of $44.68 billion, a price-to-earnings ratio of 43.97, a PEG ratio of 2.62 and a beta of 1.45.

Kenvue (NYSE:KVUE) last released its quarterly earnings results on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, hitting the consensus estimate of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. As a group, analysts anticipate that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th will be given a $0.205 dividend. The ex-dividend date of this dividend is Wednesday, February 12th. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.52%. Kenvue’s dividend payout ratio (DPR) is presently 154.72%.

Analyst Upgrades and Downgrades

A number of research firms recently commented on KVUE. UBS Group lowered their price target on shares of Kenvue from $23.00 to $21.00 and set a “neutral” rating on the stock in a report on Friday, February 7th. Deutsche Bank Aktiengesellschaft cut shares of Kenvue from a “buy” rating to a “hold” rating and lowered their price target for the stock from $25.00 to $24.00 in a report on Thursday, December 12th. Citigroup lowered their price target on shares of Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a report on Wednesday, January 15th. Canaccord Genuity Group lowered their price target on shares of Kenvue from $27.00 to $24.00 and set a “buy” rating on the stock in a report on Friday, February 7th. Finally, Barclays lowered their price target on shares of Kenvue from $23.00 to $21.00 and set an “equal weight” rating on the stock in a report on Friday, January 17th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $23.00.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.